{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:29:28Z","timestamp":1787585368282,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nbd.2026.107480","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:45:23Z","timestamp":1781333123000},"page":"107480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bioenergetic dysregulation in the basal ganglia and cerebellum of patients with premanifest and manifest Huntington's disease"],"prefix":"10.1016","volume":"227","author":[{"given":"Jannik","family":"Prasuhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian G.","family":"K\u00f6dderitzsch Mertins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta M.","family":"Pokotylo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke-Lina","family":"A\u00dfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"van Well","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Henkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Uter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Loens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"M\u00fcnchau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.nbd.2026.107480_bb0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1212\/WNL.0000000000001214","article-title":"Triheptanoin improves brain energy metabolism in patients with Huntington disease","volume":"84","author":"Adanyeguh","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2026.107480_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.toxlet.2023.04.011","article-title":"Mitochondrial dysfunction, oxidative stress, ER stress and mitochondria-ER crosstalk alterations in a chemical rat model of Huntington\u2019s disease: potential benefits of bezafibrate","volume":"381","author":"Brondani","year":"2023","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.nbd.2026.107480_bb0015","doi-asserted-by":"crossref","unstructured":"Cao, L. et al. (2024) \u201cIdentifying and verifying Huntington's disease subtypes: clinical features, neuroimaging, and cytokine changes,\u201d Brain Behav., 14(3), p. e3469. Available at: doi:https:\/\/doi.org\/10.1002\/brb3.3469.","DOI":"10.1002\/brb3.3469"},{"issue":"4","key":"10.1016\/j.nbd.2026.107480_bb0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/18796397251366313","article-title":"Understanding the relationship between patient-reported outcome measures, clinician-rated assessments, and performance-based measures (cognitive tests and device-based estimates) of symptoms and functioning in people with Huntington\u2019s disease","volume":"14","author":"Carlozzi","year":"2025","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.nbd.2026.107480_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117026","article-title":"AssemblyNet: a large ensemble of CNNs for 3D whole brain MRI segmentation","volume":"219","author":"Coup\u00e9","year":"2020","journal-title":"NeuroImage"},{"key":"10.1016\/j.nbd.2026.107480_bb0030","doi-asserted-by":"crossref","unstructured":"de Azevedo, P.C. et al. (2017) \u201cCerebellar gray matter alterations in Huntington disease: a voxel-based morphometry study,\u201d Cerebellum (London, England), 16(5\u20136), pp. 923\u2013928. Available at: doi:https:\/\/doi.org\/10.1007\/s12311-017-0865-6.","DOI":"10.1007\/s12311-017-0865-6"},{"issue":"2","key":"10.1016\/j.nbd.2026.107480_bb0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12311-020-01198-4","article-title":"The role of the cerebellum in Huntington\u2019s disease: a systematic review","volume":"20","author":"Franklin","year":"2021","journal-title":"Cerebellum"},{"key":"10.1016\/j.nbd.2026.107480_bb0040","doi-asserted-by":"crossref","unstructured":"Gulzar, M. et al. (2025) \u201cTherapeutic strategies for Huntington's disease: current approaches and future direction,\u201d Neurodegenerative Dis. Manag., pp. 1\u201315. Available at: doi:https:\/\/doi.org\/10.1080\/17582024.2025.2552593.","DOI":"10.1080\/17582024.2025.2552593"},{"issue":"R2","key":"10.1016\/j.nbd.2026.107480_bb0045","doi-asserted-by":"crossref","first-page":"R254","DOI":"10.1093\/hmg\/ddab170","article-title":"Huntington\u2019s disease: nearly four decades of human molecular genetics","volume":"30","author":"Gusella","year":"2021","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.nbd.2026.107480_bb0050","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.50.4.1033","article-title":"Quantitative proton-decoupled31 P MRS and1 H MRS in the evaluation of Huntington\u2019s and Parkinson\u2019s diseases","volume":"50","author":"Hoang","year":"1998","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.nbd.2026.107480_bb0055","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.4103\/1673-5374.360289","article-title":"Mitochondria in Huntington\u2019s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies","volume":"18","author":"Jurcau","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"5","key":"10.1016\/j.nbd.2026.107480_bb0060","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12311-022-01473-6","article-title":"Physiological recordings of the cerebellum in movement disorders","volume":"22","author":"Kumar","year":"2022","journal-title":"Cerebellum"},{"issue":"24","key":"10.1016\/j.nbd.2026.107480_bb0065","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201288","article-title":"Assessment of Bioenergetic Deficits in Patients With Parkinson Disease and Progressive Supranuclear Palsy Using31 P-MRSI","volume":"99","author":"Prasuhn","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nbd.2026.107480_bb0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s10020-021-00426-9","article-title":"Relationship between brain iron deposition and mitochondrial dysfunction in idiopathic Parkinson\u2019s disease","volume":"28","author":"Prasuhn","year":"2022","journal-title":"Mol. Med."},{"key":"10.1016\/j.nbd.2026.107480_bb0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2022.05.008","article-title":"The cerebellar bioenergetic state predicts treatment response in COQ8A-related ataxia","volume":"99","author":"Prasuhn","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"10.1016\/j.nbd.2026.107480_bb0080","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ana.26884","article-title":"Levodopa impairs the energy metabolism of the basal ganglia In Vivo","volume":"95","author":"Prasuhn","year":"2024","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2026.107480_bb0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neurad.2021.11.006","article-title":"Energy metabolism measured by 31P magnetic resonance spectroscopy in the healthy human brain","volume":"49","author":"Rietzler","year":"2022","journal-title":"J. Neuroradiol."},{"key":"10.1016\/j.nbd.2026.107480_bb0090","doi-asserted-by":"crossref","unstructured":"Roiboit, C.M. and Stout, J.C. (2025) \u201cCognitive endpoints in Huntington's disease trials: a conceptual framework for clinical meaningfulness,\u201d Mov. Disord. Clin. Pract., p. mdc3.70298. doi:https:\/\/doi.org\/10.1002\/mdc3.70298.","DOI":"10.1002\/mdc3.70298"},{"issue":"1","key":"10.1016\/j.nbd.2026.107480_bb0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/mds.27174","article-title":"Movement disorders in genetically confirmed mitochondrial disease and the putative role of the cerebellum","volume":"33","author":"Schreglmann","year":"2018","journal-title":"Mov. Disord."},{"issue":"14","key":"10.1016\/j.nbd.2026.107480_bb0100","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2174\/1389450122666210224105945","article-title":"Mitochondrial dysfunction in Huntington\u2019s disease: pathogenesis and therapeutic opportunities","volume":"22","author":"Sharma","year":"2021","journal-title":"Curr. Drug Targets"},{"issue":"6","key":"10.1016\/j.nbd.2026.107480_bb0105","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s11011-021-00844-y","article-title":"Metabolism in Huntington\u2019s disease: a major contributor to pathology","volume":"37","author":"Singh","year":"2022","journal-title":"Metab. Brain Dis."},{"issue":"7","key":"10.1016\/j.nbd.2026.107480_bb0110","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: the integrated staging system","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.nbd.2026.107480_bb0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JHD-200413","article-title":"Brain bio-energetic state does not correlate to muscle mitochondrial function in Huntington\u2019s disease","volume":"9","author":"Van Diemen","year":"2020","journal-title":"J. Huntingtons Dis."},{"issue":"3","key":"10.1016\/j.nbd.2026.107480_bb0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14728214.2021.1962285","article-title":"Emerging therapeutics in Huntington\u2019s disease","volume":"26","author":"Wiggins","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.nbd.2026.107480_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149246","article-title":"Altered anterograde axonal transport of mitochondria in cultured striatal neurons of a knock-in mouse model of Huntington\u2019s disease","volume":"691","author":"Wu","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.nbd.2026.107480_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2025.115423","article-title":"Selective striatal pathological changes in a novel human HTT exon 1 knock-in mouse model of Huntington\u2019s disease","volume":"394","author":"Wu","year":"2025","journal-title":"Exp. Neurol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996126002251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996126002251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:54:25Z","timestamp":1787583265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996126002251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S0969996126002251"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2026.107480","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioenergetic dysregulation in the basal ganglia and cerebellum of patients with premanifest and manifest Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2026.107480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107480"}}